The Cost-Effectiveness Of Dabigatran Etexilate Compared With Warfarin And Rivaroxaban In The Treatment Of Acute Pulmonary Embolism In The Uk. | Value Health;17(7): A489, 2014 Nov. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

The Cost-Effectiveness Of Dabigatran Etexilate Compared With Warfarin And Rivaroxaban In The Treatment Of Acute Pulmonary Embolism In The Uk.

Jugrin, A V; Ustyugova, A V; Urbich, M; Lamotte, M; Sunderland, T J.

Affiliation

Jugrin AV; IMS Health HEOR, Vilvoorde, Belgium.
Ustyugova AV; Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany.
Urbich M; Boehringer Ingelheim Ltd, Bracknell, UK.
Lamotte M; IMS Health HEOR, Vilvoorde, Belgium.
Sunderland TJ; Boehringer Ingelheim, Berkshire, UK.

Value Health ; 17(7): A489, 2014 Nov.

Article in En | MEDLINE | ID: mdl-27201448

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2014 Document type: Article Affiliation country: Belgium

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2014 Document type: Article Affiliation country: Belgium